AN2 Therapeutics (ANTX) Other financing activities (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Other financing activities for 5 consecutive years, with $39000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 2.63% year-over-year to $39000.0; the TTM figure through Mar 2026 stood at $28000.0 (down 26.32% YoY), while the FY2025 annual figure was $27000.0, down 88.0% from the prior year.
• Other financing activities improved to $39000.0 in Q1 2026 per ANTX's latest filing, from -$11000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $63.2 million in Q1 2022 and bottomed at -$11000.0 in Q2 2025.
• Historically, Other financing activities has averaged $10.1 million across 4 years, with a median of $39000.0 in 2026.
• Annual changes were most pronounced in 2022 — Other financing activities soared 631880.0% — and 2025, when it tumbled 83.11%.
• AN2 Therapeutics' Other financing activities stood at -$10000.0 in 2022, then soared by 2350.0% to $225000.0 in 2024, then plunged by 104.89% to -$11000.0 in 2025, then jumped by 454.55% to $39000.0 in 2026.
• Business Quant data shows ANTX's Other financing activities at $39000.0 in Q1 2026, -$11000.0 in Q2 2025, and $38000.0 in Q1 2025.